Cited by 253Protein Degradation and InhibitorsCytokine Signaling Pathways and InteractionsChemical Synthesis and Analysis

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Open access

Zhou, Haibin, Bai, Longchuan, Xu, Renqi, Zhao, Yujun, Chen, Jianyong, McEachern, Donna, Chinnaswamy, Krishnapriya, Wen, Bo, Dai, Lipeng, Kumar, Praveen, Yang, Chao-Yie, Liu, Zhaomin, Wang, Mi, Liu, Liu, Meagher, Jennifer L., Yi, Han, Sun, Duxin, Stuckey, Jeanne A., Wang, Shaomeng·2019·Journal of Medicinal Chemistry

DOI 10.1021/acs.jmedchem.9b01530PMC PMC8848307

Open this paper in CoChat — free account

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases. Despite 20 years of persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery of potent small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept. We first designed SI-109 as a potent, small-molecule inhibitor of the STAT3 SH2 domain. Employing ligands for cereblon/cullin 4A E3 ligase and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36. SD-36 induces rapid STAT3 degradation at low nanomolar concentrations in cells and fails to degrade other STAT proteins. SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3. A single dose of SD-36 results in complete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues. SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules. SD-36 is a potent, selective, and efficacious STAT3 degrader.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b01530

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery
Vilar, S., Cozza, G., & Moro, S. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786786624 · Cited by 1,200

Flagged first, then by citations

Show all 40 references

Research works printed but not linked: 2

Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version, 2.10.3; Global Phasing Ltd.: Cambridge, U.K., 2017.
Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G. GRADE, version 1.2.13; Global Phasing Ltd.: Cambridge, U.K., 2017.

Sorted by citations

Items 101–200 of 253

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
Yim, J., Park, J., Kim, G., Lee, H. H., Chung, J. S., Jo, A., Koh, M., & Park, J. (2024) · ChemMedChem · doi:10.1002/cmdc.202400326 · Cited by 28
Validating Signal Transducer and Activator of Transcription (STAT) Protein–Inhibitor Interactions Using Biochemical and Cellular Thermal Shift Assays
Attarha, S., Reithmeier, A., Busker, S., Desroses, M., & Page, B. D. G. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00046 · Cited by 24
Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo
Yue, P., Zhu, Y., Brotherton‐Pleiss, C., Fu, W., Verma, N., Chen, J., Nakamura, K., Chen, W., Chen, Y., Alonso-Valenteen, F., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215613 · Cited by 24
Self-citation
Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
Ibrahim, S., Khan, M. U., Khurram, I., Rehman, R., Rauf, A., Ahmad, Z., Aljohani, A. S. M., Abdulmonem, W. A., & Quradha, M. M. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70011 · Cited by 27
Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
Anaya, Y. A., Barragan, M., Bracho, R. P., Shaham, S. H., Bandyopadhyay, D., George, E., Nguyen, D. D. T., & Tripathi, M. K. (2025) · Cancer · doi:10.1002/cncr.70132 · Cited by 26
Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Severini, L. L., Bufalieri, F., Infante, P., & Marcotullio, L. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.854352 · Cited by 23
Developments of PROTACs technology in immune-related diseases
Wang, C., Zhang, Y., Deng, J., Liang, B., & Xing, D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115127 · Cited by 23
Bifunctional Molecules beyond PROTACs
Conway, S. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00293 · Cited by 23
The Peptide PROTAC Modality: A New Strategy for Drug Discovery
Zhu, Y., Dai, Y., & Tian, Y. (2025) · MedComm · doi:10.1002/mco2.70133 · Cited by 24
Advancing Design Strategy of PROTACs for Cancer Therapy
Luo, H., Tian, Y., Abdullah, R., Zhang, B., Ma, Y., & Zhang, G. (2025) · MedComm · doi:10.1002/mco2.70258 · Cited by 24
Transcription Factors and Methods for the Pharmacological Correction of Their Activity
Guryanova, S. V., Maksimova, T. V., & Мухамедовна, А. М. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136394 · Cited by 23
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer
Li, H., Wang, L., Cao, F., Yu, D., Yang, J., Yu, X., Dong, J., Qin, J., & Guan, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944455 · Cited by 19
Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Zhou, Y., Xu, S., López‐Carrobles, N., Ding, D., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0019 · Cited by 20
Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation
Wang, W., McDonald, M. C. L., Hariprasad, R., Hamilton, T., & Frank, D. A. (2024) · Cancers · doi:10.3390/cancers16071387 · Cited by 21
Cellular parameters shaping pathways of targeted protein degradation
Cardno, A., Kennedy, B., & Lindon, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08104-w · Cited by 22
Synthesis of benzo[ b ][1,5]diazocin-6(5 H )-one derivatives via the Cu-catalysed oxidative cyclization of 2-aryl-1 H -indoles with 1,1-enediamines
Chen, Y., Yang, J., Lu, Z., Zhao, K.-H., Xie, Q., & Yan, S. (2023) · Chemical Communications · doi:10.1039/d2cc06388c · Cited by 17
Targeting STAT3 and STAT5 in Cancer
de Araujo, E. D., Keserű, G. M., Gunning, P. T., & Moriggl, R. (2020) · Cancers · doi:10.3390/cancers12082002 · Cited by 17
Design and pharmaceutical applications of proteolysis-targeting chimeric molecules
Liang, Y., Nandakumar, K. S., & Cheng, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114211 · Cited by 16
Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
Kounde, C. S., & Tate, E. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01542 · Cited by 17
Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment
Huang, L. H., Shao, J., Lai, W., Gu, H., Yang, J., Shi, S., Wufoyrwoth, S., Song, Z., Zou, Y., Xu, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116159 · Cited by 16
Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3
Suo, Y., Du, D., Chen, C., Zhu, H., Wang, X., Song, N., Lu, D., Yang, Y., Li, J., Wang, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02371 · Cited by 15
Self-citation
IL-4–STAT6 axis amplifies histamine-induced vascular endothelial dysfunction and hypovolemic shock
Krempski, J. W., Yamani, A. N., Thota, L. N., Marella, S., Ganesan, V., Sharma, A., Kaneshige, A., Bai, L., Zhou, H., Foster, P. S., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.05.009 · Cited by 17
Self-citation
Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5
Fei, W.-L., Wang, Y., Feng, Q.-L., Li, C.-T., Jiang, R.-X., Zhang, S.-D., Pan, Y., Ni, P.-F., Huang, F.-R., Huangfu, Y.-B., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117183 · Cited by 15
Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3)
Huang, Q., Zhong, Y., Li, B., Ouyang, S., Deng, L., Mo, J., Shi, S., Lv, N., Wu, R., Liu, P., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113525 · Cited by 15
Recent advances in targeting protein degradation for tumor immunotherapy
Li, S., Jin, Y., Wu, H., Yuan, H., & Zhao, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01765-4 · Cited by 14
Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications
Haikarainen, T., Virtanen, A. T., Cravatt, B. F., & Silvennoinen, O. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01336-9 · Cited by 17
Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3
Deng, L., Mo, J., Zhang, Y., Peng, K., Li, H., Ouyang, S., Feng, Z., Fang, W., Wei, J., Rong, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00940 · Cited by 14
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14
Chimera induced protein degradation: PROTACs and beyond
Yin, L., & Hu, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112494 · Cited by 14
Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3Preprint
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 14
Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8 + Effector T-Cell Function for Synergistic Cancer Immunotherapy
Ao, K., Sun, Z., Hao, Y., Qin, J., Xu, C., Wen, X., Yang, Z., Li, L., Gan, S., Chen, X., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00812 · Cited by 13
Self-citation
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis
Acharyya, R. K., Kothapalli, Y., Yarlagadda, S., De, C. K., Allu, S. R., Roy, J., & Rej, R. K. (2025) · Molecules · doi:10.3390/molecules31010033 · Cited by 13
Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors
Dai, M., Sridhar, R., Li, R., Tan, R., Yan, K., Fan, G., & Liu, M. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221095950 · Cited by 14
PROTACs: The Future of Leukemia Therapeutics
Anwar, Z., Ali, M. S., Galvano, A., Perez, A., Mantia, M. L., Bukhari, I., & Świątczak, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851087 · Cited by 13
RETRACTED: Application of Carboxylic Acid Bioisosteres in Drug Structure Optimization
Luo, X., Yu, D., Li, X., Zhang, Y., Deng, C., & Zhang, W. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118104 · Cited by 15
Retracted
Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity
Pierri, M., Liu, X., Kroupova, A., Rutter, Z. J., Hallatt, A. J., & Ciulli, A. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129861 · Cited by 13
PROTAC: A Novel Technology for Drug Development**
Li, J., & Liu, J. (2020) · ChemistrySelect · doi:10.1002/slct.202003162 · Cited by 13
Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy
Chen, L., Wan, X., Shan, X., Zha, W., & Fan, R. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00586-2 · Cited by 13
Cell-based relay delivery strategy in biomedical applications
Chen, Y., Pal, S., & Hu, Q. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114871 · Cited by 12
Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway
Li, H., Ouyang, S., Zhang, Y., Peng, K., Fang, W., Liu, Z., Wang, C., Zhang, X., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114858 · Cited by 11
Self-citation
Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)
Wang, F., Cao, X., Lin, G., Tian, P., & Gao, D. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2056013 · Cited by 10
Age‐associated myeloid malignancies – the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia
Fasouli, E. S., & Katsantoni, E. Z. (2024) · FEBS Letters · doi:10.1002/1873-3468.14985 · Cited by 12
Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9
Harnessing the Power of Natural Products for Targeted Protein Degradation
Zhu, B., Wu, Z., Shou, Y., Zhao, K., Lu, Q., Qin, J., & Guo, H. (2025) · Medicinal Research Reviews · doi:10.1002/med.22113 · Cited by 12
Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation
Nafie, M. S., Diab, M. K., Yassen, A. S. A., Elshamy, A. M., Tohamy, M. R. E., Tawfik, H. O., & Fahmy, S. A. (2025) · Drug Development Research · doi:10.1002/ddr.70192 · Cited by 9
PROTACs coupled with oligonucleotides to tackle the undruggable
Zhang, G., Yan, S., Liu, Y., Du, Z., Min, Q., & Qin, S. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2459528 · Cited by 9
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Li, P., Li, B., Yang, N., Xu, T., & Zheng, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2262176 · Cited by 8
Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review)
Cheng, H., Chen, L., & Huang, C. (2025) · Oncology Letters · doi:10.3892/ol.2025.14881 · Cited by 7
Structural optimization and characterization of highly potent and selective STAT3 inhibitors for the treatment of triple negative breast cancer
Jin, W., Zhang, Y., Wang, B., Kang, Z., Li, H., Song, J., Chen, Y., Xiong, H., & Chen, J. W. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117332 · Cited by 7
Self-citation
Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
Ying, S., Chi, H., Xiao-qiu, W., Zeng, P., Chen, J., Fu, T., Fu, W., Zhang, P., & Tan, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02417 · Cited by 8
Self-citation
Reductive C(sp2)–C(sp3) Coupling Protocol to Enable Linker Exploration of Cereblon E3-Ligase BRD4 Proteolysis-Targeting Chimeras
Lovato, K., Loskot, D., Gelin, C. F., Zhu, L., Chaudhry, C., Vellore, N. A., Rosario, A. M. D., Courtney, T. M., Miller, S. P., Cho, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03157 · Cited by 7
Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
Wu, Y., Zhang, J., Zhu, X., & Zhang, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215808 · Cited by 8
SD‐36 promotes growth inhibition and induces apoptosis via suppression of Mcl‐1 in glioma
Kong, S., Ge, X., Li, X., Liu, Z., Zhang, R., Yang, M., Wang, Z., & Li, Z. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16754 · Cited by 7
Self-citation
Design, synthesis, and biological evaluation of novel (E)-2-cyano-3-(4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl) derivatives as potent STAT3-targeting anticolorectal cancer agents
Jiang, W., Liu, P., Zhao, Z., Fan, D., He, X., Jiang, Y., & Yang, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107955 · Cited by 6
Linkerology in PROTACs: learnings for proximity-inducing therapeutics
Prieto‐Díaz, R., Urbina, A., Rodriguez-Rios, M., & Ciulli, A. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.07.004 · Cited by 7
Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells
Oh, Y.-T., Chen, Z., Wang, D., Ramalingam, S. S., & Sun, S. (2025) · Oncogene · doi:10.1038/s41388-025-03381-5 · Cited by 6
Design and synthetic approaches to thalidomide based small molecule degraders
Kumar, A., Kumar, G., Kalia, N., & Sahoo, P. R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117700 · Cited by 6
Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
Gleicher, S., Porter, B. A., Nath, D., Li, G., Khanna, R., Goldberg, H., Kortylewski, M., Bratslavsky, G., & Kotula, L. (2021) · Cancers · doi:10.3390/cancers13102426 · Cited by 5
Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3Preprint
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303 · Cited by 6
STAT3 at the tumor-immune interface: mechanisms of immune escape and therapeutic opportunities
Cheng, X., Jing, H., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1850359 · Cited by 5
Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia
Li, Y., Seet, C. S., Mack, R. M., Joshi, K., Runde, A. P., Hagen, P. A., Barton, K., Breslin, P., Kini, A. R., Ji, H., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.11.003 · Cited by 5
Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer – Current status and future outlooks
Malekinejad, Z., Aghdam, E. M., Ardakan, A. K., Forghan, E., Alizadeh, M., Simiyari, R., Heidari, H. R., & Montazersaheb, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178079 · Cited by 7
Azetidine ring, salicylic acid, and salicylic acid bioisosteres as determinants of the binding characteristics of novel potent compounds to Stat3
Chen, Y., Zhai, N., Zhu, Y., Yue, P., Verma, N., Brotherton‐Pleiss, C., Fu, W., Nakamura, K., Chen, W., Kawakami, J. K., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129565 · Cited by 5
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5
Discovery of a potent and selective PROTAC degrader for STAT3
Wang, K., Zheng, Y., Mao, W., Xu, J., & Wang, Y. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00260e · Cited by 5
PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 4
STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome
Pellerino, A., Priego, N., Bertero, L., Ricci, A. A., Mangherini, L., Bruno, F., Beano, A., Mittica, G., Mistrangelo, M., Garbossa, D., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf187 · Cited by 4
Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics
Huang, M., Wei, F., Cao, J., & Jiang, H. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108985 · Cited by 4
Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer
Lin, L., Zheng, F., Wei, H., Wu, X., Yan, H., & Ding, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118432 · Cited by 4
Extracellular matrix stiffness in hepatocellular carcinoma: mechanisms and targeted therapeutic strategies
Zhou, Z., & Xu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773909 · Cited by 5
Revealing the Role of Beesioside O from Actaea vaginata for the Treatment of Breast Cancer Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation
Li, S., Lü, J., Xue, H., Lou, Y., Liu, J., Wang, Y., Wu, H., & Chen, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052283 · Cited by 4
Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents
Xu, J., Kim, H.-J., Dong, J., Chen, H., Xu, J., Ma, R., Zhou, M., Wang, T., Shen, Q., & Zhou, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114229 · Cited by 4
Advancements in Small Molecule PROTACs Containing Indole/Spiro-fused Oxindole Scaffolds: An Emerging Degrader Targeting Cancers
Li, X., Liu, Y., Huang, W., Xie, X., Zhu, H., Peng, C. Y., & Han, B. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220509175305 · Cited by 3
Preclinical Studies of PROTACs in Hematological Malignancies
Fuchs, O., & Bokorová, R. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210308111546 · Cited by 3
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
Pophali, P. A., Desai, S. R., & Shastri, A. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00693-9 · Cited by 3
Small Molecule Induces Time‐Dependent Inhibition of Stat3 Dimerization and DNA‐Binding Activity and Regresses Human Breast Tumor Xenografts
Yue, P., Chen, Y., Ogese, M. O., Sun, S., Zhang, X., Esan, T., Buolamwini, J. K., & Turkson, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400351 · Cited by 3
C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy
Zhu, C., Li, Y., Xu, H., Sun, L., Wei, Y., 马承娴, Chen, Q., & He, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02682-9 · Cited by 4
Nickel‐Catalyzed Cross‐Coupling of Bromodifluoromethylphosphonates with Arylboron Reagents
Kuriyama, M., Maeda, G., Kamata, K., Kodama, Y., Yamamoto, K., & Onomura, O. (2022) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202201140 · Cited by 2
Protective effects and regulatory mechanisms of Shen-shuai-yi recipe on renal fibrosis in unilateral ureteral obstruction-induced mice
Lin, P., Weng, T.-T., Duan, L., Zhang, L.-Z., Wei, X., Qi, S., You, J.-W., Cao, Y., Ge, G., Liu, W., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17908 · Cited by 2
Silver-Catalyzed Cascade Approach to Access Fused Pyrazolo-naphthyridine and -isoquinoline Backbones and Investigation of Their Photophysical Properties
Mobarakeh, F. A., Rezaei-Gohar, M., Amiri, K., Bijanzadeh, H. R., Röminger, F., & Balalaie, S. (2025) · ACS Omega · doi:10.1021/acsomega.4c11109 · Cited by 2
Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay
Li, E., Hu, X., Hu, L., Li, Y., Zhao, J., Wang, J., Mou, Y., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01820 · Cited by 2
Synthesis of the Key Intermediate of SM-406 (Xevinapant) and Its Analogues
Zhang, Y., Wang, Y., Xie, G., Chen, J., Hu, A., Wang, R., He, T., Duolikun, D., & Sun, H. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c01173 · Cited by 2
Self-citation
Targeted Protein Degradation by Proteolysis Targeting Chimeras
Du, W. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch11 · Cited by 2
Advancing proteolysis targeting chimeras toward clinical drug developments
Tian, X., Huang, C., Yin, L., & Yu, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00007-8 · Cited by 1
Biaryl Phosphate‐Based Inhibitors of the Transcription Factor STAT4
Brovchenko, N., Oelsch, A. M., Protzel, C., & Berg, T. (2025) · ChemMedChem · doi:10.1002/cmdc.202500672 · Cited by 1
The role of LncRNA SNHG3 in human cancers
Tang, J., Su, M., Xiao, Y., Ou, W., Wang, W., Peng, R., & Wu, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03640-7 · Cited by 1
Bifunctional proximity-inducing strategies for targeted and programmable post-translational modifications
Tanga, S., Das, P., Samoi, T. B., Hota, A., Karmakar, A., & Maji, B. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115874 · Cited by 1
Kinetic control of macrophage death by PTM-turnover crosstalk in infection and inflammation
Saha, S., Verma, R., & Nita‐Lazar, A. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.04.011 · Cited by 2
Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration
Acharyya, R. K., Bai, L., Zhou, H., Wu, D., Wang, M., Metwally, H., McEachern, D., Wang, M., Wen, B., Sun, D., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00743 · Cited by 1
Self-citation
Screening of the antiproliferative activity of lycopene isomers in a panel of human cancer cell lines: Lycopene Z-isomers exhibit greater activity than the all-E-isomer
Honda, M., Matsumoto, K., Gayatri, A., Ito, M., Sawada, K., & Nakamura, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-65208-x · Cited by 1
PROTACs in Treatment of Glioma
Kumar, S., & Maharshi, V. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_15 · Cited by 1
A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy
Zhang, S., Wu, N., Geng, Y., Guan, L., Niu, M., Li, J., & Zhu, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1560559 · Cited by 2
Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy
Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1
Strategies for Targeting the JAK ‐ STAT Pathway in Lymphoid Malignancies
Feith, D. J., Ung, J., Elghawy, O., Yue, P., Turkson, J., & Loughran, A. T. P. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch27 · Cited by 1
WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
Self-citation
Retracted
Idegenerering i IT-bedrifter - åpenhet og nettverks betydning for idégenerering
Liafjell, T. A. (2014) · NORA - Norwegian Open Research Archives
Celebrating the Medicinal Chemistry of Gunda Georg and Shaomeng Wang
Bolognesi, M. L., & Conway, S. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01917
Deletion of Smooth Muscle Lethal Giant Larvae 1 Promotes Neointimal Hyperplasia in Mice
Zhang, Y. P., Yuan, P., Ma, X., Deng, Q., Gao, J., Yang, J., Zhang, T., Zhang, C., & Zhang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.834296

Authors: Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., Yang, C.-Y., Liu, Z., Wang, M., Liu, L., Meagher, J. L., Yi, H., Sun, D., Stuckey, J. A., & Wang, S.
Affiliations: University of Michigan (US)
Corresponding author: Wang, Shaomeng
ORCID: Zhou, Haibin
Bai, Longchuan
Zhao, Yujun
Chen, Jianyong
McEachern, Donna
Wen, Bo
Kumar, Praveen
Yang, Chao-Yie
Liu, Zhaomin
Wang, Mi
Liu, Liu
Meagher, Jennifer L.
Sun, Duxin
Stuckey, Jeanne A.
Wang, Shaomeng
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2019-11-20
Volume: 62
Issue: 24
Pages: 11280-11300
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/acs.jmedchem.9b01530
PMC: PMC8848307
OpenAlex: W2990256176
Cited by: 233
References: 40
Citations by year: 2026: 26 · 2025: 43 · 2024: 31 · 2023: 33 · 2022: 44 · 2021: 28 · 2020: 27
FWCI: 8.85
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-045 (stm-asf)
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P30 CA046592)
Comprehensive Cancer Center, University of Michigan
Oncopia Therapeutics Inc.
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: STAT3, PROTACs, small-molecule degraders, SH2 domain inhibitors, structure-based drug design, leukemia, lymphoma, xenograft tumor regression, protein degradation
MeSH terms: Animals, Antineoplastic Agents, Azocines, Female, Humans, Indoles, Protein Conformation, Tissue Distribution, Tumor Cells, Cultured, Drug Design, Molecular Structure, Leukemia, Myeloid, Acute, Mice, SCID, Apoptosis, Xenograft Model Antitumor Assays, Cell Proliferation, STAT3 Transcription Factor, Mice, Drug Discovery, Proteolysis, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks